IDH2 and central nervous system cancer: The results from the INDIGO trial [65] on the IDH inhibitor, Vorasidenib showed a significant improvement in progression-free survival (PFS) and delayed time to next treatment among patients harboring grade 2 IDH mutant gliomas per WHO 2016 Classification without contrast-enhancement on MRI and not previously treated with radio- or chemotherapy, whereas gliomas showing contrast-enhancement on MRI experimented much less benefit in terms of radiological response to this drug [66].